{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:45:56Z","timestamp":1776278756523,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.schres.2012.07.029","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T00:46:16Z","timestamp":1346719576000},"page":"144-152","source":"Crossref","is-referenced-by-count":89,"title":["Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: Comparison with reference dose risperidone, 6mg\/day"],"prefix":"10.1016","volume":"141","author":[{"given":"Herbert Y.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio","family":"Elkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"van Kammen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli","family":"Hacksell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2012.07.029_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.07.029_bb0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response \u2014 a double-blind PET study in schizophrenia","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.07.029_bb0015","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.pnpbp.2008.08.020","article-title":"Effect of ritanserin, a 5HT2A\/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.neuropharm.2011.05.023","article-title":"Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors","volume":"61","author":"Albizu","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2012.07.029_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sleep.2010.10.004","article-title":"Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers","volume":"12","author":"Ancoli-Israel","year":"2011","journal-title":"Sleep Med."},{"key":"10.1016\/j.schres.2012.07.029_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety","volume":"66","author":"Anil Yagcioglu","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.1995.tb14977.x","article-title":"The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors","volume":"115","author":"Bonhaus","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.07.029_bb0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/(SICI)1099-1166(199807)13:7<473::AID-GPS800>3.0.CO;2-Z","article-title":"Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment","volume":"13","author":"Byne","year":"1998","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s007020050144","article-title":"The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice","volume":"106","author":"Carlsson","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2012.07.029_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.schres.2012.07.029_bb0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1192\/bjp.bp.108.049395","article-title":"Mortality and tardive dyskinesia: long-term study using the US National Death Index","volume":"194","author":"Dean","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0075","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.npp.1301656","article-title":"Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients","volume":"33","author":"Erritzoe","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.07.029_bb0080","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.schres.2012.07.029_bb0090","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.107.121715","article-title":"ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models","volume":"322","author":"Gardell","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2012.07.029_bb0095","series-title":"ECDEU assessment manual for psychopharmacology Rev Rockville: Alcohol, Drug Abuse, and Mental Health Administration","first-page":"217","volume":"76\u2013338","year":"1976"},{"key":"10.1016\/j.schres.2012.07.029_bb0100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbn171","article-title":"Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?","volume":"35","author":"Harvey","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.07.029_bb0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine and Risperidone Enhancement (CARE) Study Group","volume":"354","author":"Honer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.07.029_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2012.07.029_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-011-2251-2","article-title":"Interaction of mGlu2\/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats","volume":"217","author":"Horiguchi","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2012.07.029_bb0120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4088\/JCP.v67n0606","article-title":"Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses","volume":"67","author":"Hugenholtz","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical APDs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2012.07.029_bb9000","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/7854_2010_42","article-title":"Neurocognition in schizophrenia","volume":"4","author":"Kalkstein","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.schres.2012.07.029_bb0140","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.schres.2012.07.029_bb0130","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1176\/ajp.153.7.948","article-title":"High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study","volume":"153","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2012.07.029_bb0145","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.07.029_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2011.01.011","article-title":"Neurocognition in schizophrenia","volume":"127","author":"Keshavan","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.07.029_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.07.029_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical APDs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.07.029_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(98)00145-5","article-title":"A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia","volume":"37","author":"Lee","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.07.029_bb0180","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2000","journal-title":"Lancet"},{"issue":"493","key":"10.1016\/j.schres.2012.07.029_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","article-title":"Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain","volume":"16","author":"Li","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of APDs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.07.029_bb0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchemneu.2004.09.001","article-title":"5-HT1A receptor mRNA and immunoreactivity in the rat medial septum\/diagonal band of Broca-relationships to GABAergic and cholinergic neurons","volume":"29","author":"L\u00fcttgen","year":"2005","journal-title":"J. Chem. Neuroanat."},{"issue":"Suppl. 5","key":"10.1016\/j.schres.2012.07.029_bb0200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00406-008-5011-5","article-title":"From genes to psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia","volume":"258","author":"Maier","year":"2008","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2012.07.029_bb0205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0215","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF01277672","article-title":"The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin","volume":"104","author":"Martin","year":"1997","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2012.07.029_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004714-198606000-00002","article-title":"Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study","volume":"6","author":"McEvoy","year":"1986","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0220","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia.A controlled study of the neuroleptic threshold and higher haloperidol dose","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002130050018","article-title":"An atypical compound by any other name is still an atypical","volume":"148","author":"Meltzer","year":"2000","journal-title":"Psychopharmacology"},{"issue":"7 Suppl.","key":"10.1016\/j.schres.2012.07.029_bb0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S109285290002664X","article-title":"Interpreting the efficacy findings in the CATIE study: what clinicians should know","volume":"11","author":"Meltzer","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2012.07.029_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog Brain Res."},{"key":"10.1016\/j.schres.2012.07.029_bb0280","first-page":"238","article-title":"Classification of typical and atypical APDs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2012.07.029_bb0270","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0240","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Meta-Trial Study Group Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.psychres.2010.02.018","article-title":"A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia","volume":"177","author":"Meltzer","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2012.07.029_bb0285","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.schres.2012.07.029_bb0255","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4088\/JCP.10m05997","article-title":"A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation","volume":"72","author":"Meltzer","year":"2011","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2012.07.029_bb0260","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","article-title":"The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment","volume":"213","author":"Meltzer","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2012.07.029_bb0275","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","article-title":"Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia","volume":"13","author":"Meltzer","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.schres.2012.07.029_bb0290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/oxfordjournals.schbul.a007111","article-title":"The Texas medication algorithm project: clinical results for schizophrenia","volume":"30","author":"Miller","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.07.029_bb0295","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1523\/JNEUROSCI.4230-10.2011","article-title":"Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring","volume":"31","author":"Moreno","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2012.07.029_bb0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JCP.0b013e31819294cb","article-title":"Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients","volume":"29","author":"Morrato","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0306-4522(01)00593-0","article-title":"Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group","volume":"111","author":"Nocjar","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2012.07.029_bb0310","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"Nordstrom","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2012.07.029_bb0320","first-page":"81","article-title":"Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man","volume":"10","author":"Nyberg","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0315","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0330","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0325","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0335","series-title":"Personal Communication","article-title":"D2 receptor occupancy is not required for antipsychotic response in schizophrenia: A randomized clinical trials with M100907, a 5HT2A antagonist","author":"Preda","year":"2011"},{"key":"10.1016\/j.schres.2012.07.029_bb0340","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference APDs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2012.07.029_bb9005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(94)90643-2","article-title":"Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the \u2018atypical\u2019 antipsychotics, clozapine and risperidone","volume":"264","author":"Schreiber","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0345","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2012.07.029_bb0355","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical APDs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2012.07.029_bb0360","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2012.07.029_bb0365","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D2 receptor occupancy from plasma levels of APDs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.07.029_bb0370","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N(1-methylpiperidin-4-yl)-N\u2019-(4-(2methylpropyloxy)phenylmethyl)Carbamine (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine 2A Receptor Inverse Agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2012.07.029_bb0375","first-page":"1","article-title":"Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.07.029_bb0380","first-page":"815","article-title":"Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics","volume":"4","author":"Weiner","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2012.07.029_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02245441","article-title":"An open clinical and biochemical study of ritanserin in acute patients with schizophrenia","volume":"114","author":"Wiesel","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2012.07.029_bb0395","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose\u2013response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group","volume":"154","author":"Zimbroff","year":"1997","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412004239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412004239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T21:54:57Z","timestamp":1542750897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412004239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":78,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0920996412004239"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.07.029","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}